Amgen — Feb 4, 2025 release

The Company generated $10.4 billion of free cash flow for the full year 2024 versus $7.4 billion in 2023. AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Page 10 • The Company’s fourth quarter 2024 dividend of $2.25 per share was declared on October 25, 2024, and was paid on December 9, 2024, to all stockholders of record as of November 18, 2024, representing a 6% increase from the same period in 2023. • During the fourth quarter, there were no repayments or extinguishments of debt. For the full year 2024, the Company reduced principal debt outstanding by $4.5 billion. • For the fourth quarter and full year, the Company repurchased 0.7 million shares of common stock at a total cost of $200 million. • Cash and investments totaled $12.0 billion and debt outstanding totaled $60.1 billion as of December 31, 2024. Debt leverage was approximately 4.5 times EBITDA as of December 31, 2024. $Billions, except shares Q4 ’24 Q4 ’23 YOY Δ FY '24 FY '23 YOY Δ Operating Cash Flow $ 4.8  $ 0.5  $ 4.2  $ 11.5  $ 8.5  $ 3.0  Capital Expenditures $ 0.4  $ 0.2  $ 0.1  $ 1.1  $ 1.1  $ 0.0  Free Cash Flow $ 4.4  $ 0.3  $ 4.1  $ 10.4  $ 7.4  $ 3.0  Dividends Paid $ 1.2  $ 1.1  $ 0.1  $ 4.8  $ 4.6  $ 0.3  Share Repurchases $ 0.2  $ —  $ 0.2  $ 0.2  $ —  $ 0.2  Average Diluted Shares (millions) 542  540  2  541  538  3  Note: Numbers may not add due to rounding $Billions 12/31/24 12/31/23 YTD Δ Cash and Investments $ 12.0  $ 1